CCM
SAGE

Cadian Capital Management’s Sage Therapeutics SAGE Stock Holding History

Cadian Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-107,561
Closed -$6.7M – 37
2017
Q3 		$6.7M Buy
107,561
+52,936
+97% +$4.16M 0.31% 38
2017
Q2 		$4.35M Sell
54,625
-67,500
-55% -$4.88M 0.21% 38
2017
Q1 		$8.68M Buy
+122,125
New +$7.15M 0.42% 37

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Cadian Capital Management's SAGE Position: Q4 2017 in Review

Cadian Capital Management sold out of Sage Therapeutics (SAGE) in Q4 2017, closing a stake of 107,561 shares — an estimated $6.7M sold.

Cadian Capital Management first reported a position in SAGE in Q1 2017 and held it in 3 quarters. The position peaked at $8.68M in Q1 2017. 224 funds tracked by Wall St. Rank hold SAGE as of Q4 2017.

  • Cadian Capital Management reported no remaining Sage Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Cadian Capital Management sold 107,561 Sage Therapeutics shares in Q4 2017, an estimated $6.7M.
  • Cadian Capital Management first reported a position in Sage Therapeutics in Q1 2017 and held it in 3 quarters.
  • Cadian Capital Management's Sage Therapeutics position peaked at $8.68M in Q1 2017.
  • 224 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2017.

Based on Cadian Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.